Fig. 6: SBI-756 is not cytotoxic to human CD4 + T cells, CD8 + T cells, NK cells or monocytes.
a Peripheral blood mononuclear cells (PBMCs) were obtained from healthy blood donors and were isolated as described previously.38 PBMCs (mean ± SD, n = 3) were cultured for 48 h with each agent MLN0128 (30 nM), SBI-756 (250 nM) alone or in combination with 100 nM venetoclax. Unpaired t-test vs. vehicle (DMSO) control. n = 3. *p < 0.05, **p < 0.01, ***p < 0.005 vs. DMSO control. Leukocyte subsets were distinguished by surface markers using flow cytometry. b Mouse splenocytes were isolated from C57BL/J mice. We performed B cell or T-cell purification using STEMCELL Mouse B cell or T-cell isolation kit, respectively. Next, we treated the cells as indicated for 48 h in the presence of cytokines (BAFF or IL-7), and their viability was measured using Annexin V and PI. *p < 0.05, **p < 0.01. One-sample t-test vs. control (control = B cells + BAFF; T cells + IL-7). n = 3. c Puromycin incorporation in mouse B cells (B220+) and T cell (CD3+) after 16 h of treatment with MLN0128 30 nM and SBI-756 250 nM. Data are showed as percentage of puromycin incorporation reduction vs vehicle. c vs. DMSO control. n = 4 **p < 0.01.
